Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Targeting effector memory T-cells with Kv1.3 blockers.

Heike Wulff1, Michael Pennington

  • 1University of California, Davis, Department of Medical Pharmacology, School of Medicine, Genome and Biomedical Sciences Facility, Davis, CA 95616, USA. hwulff@ucdavis.edu

Current Opinion in Drug Discovery & Development
|July 31, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mitochondria-Targeting Moieties Based on N-Tethered Pyridinium Cations.

Angewandte Chemie (International ed. in English)·2026
Same author

Translating Science into Practice Using University-State Government Partnerships: The EPIS Model.

Prevention science : the official journal of the Society for Prevention Research·2026
Same author

Structural basis for the subtype-selective activation of K<sub>Ca</sub>3.1 channels.

Structure (London, England : 1993)·2026
Same author

Kv1.3 as an upstream regulator of oxidative stress-mediated neuroinflammation following organic dust exposure in murine <i>in vitro</i>, <i>ex vivo</i>, and <i>in vivo</i> models.

Frontiers in toxicology·2026
Same author

New mitochondrial K<sub>V</sub>1.3 conjugates are potent and specific inducers of apoptosis in cancer models.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
Same author

Kv1.3 inhibition alleviates neuropathology via neuroinflammatory and resilience pathways in a mouse model of Aβ pathology.

bioRxiv : the preprint server for biology·2026

The voltage-gated potassium channel Kv1.3 is a promising target for autoimmune diseases. Inhibitors are being developed to selectively suppress T-cells involved in conditions like multiple sclerosis and rheumatoid arthritis.

Area of Science:

  • Immunology
  • Pharmacology
  • Channelopathies

Background:

  • The voltage-gated potassium channel Kv1.3 was initially explored for general immunosuppression.
  • Kv1.3 is now recognized for its selective role in effector memory T-cells.

Purpose of the Study:

  • To summarize the role of Kv1.3 in autoimmune diseases.
  • To review the development of Kv1.3 inhibitors (peptidic and small-molecule).
  • To discuss the validation of Kv1.3 as a therapeutic target.

Main Methods:

  • Literature review of Kv1.3 function in T-cells.
  • Analysis of drug development strategies for Kv1.3 inhibitors.
  • Evaluation of preclinical and clinical data for Kv1.3 targeting.

Main Results:

Related Experiment Videos

  • Kv1.3 plays a critical role in T-cell mediated autoimmune diseases.
  • Progress has been made in developing both peptidic and small-molecule Kv1.3 inhibitors.
  • Kv1.3 is validated as a druggable target for autoimmune conditions.

Conclusions:

  • Kv1.3 is a key target for selective immunosuppression in autoimmune diseases.
  • Therapeutic strategies targeting Kv1.3 show potential for treating multiple sclerosis, type 1 diabetes, rheumatoid arthritis, and psoriasis.